Re: National Coverage Determination Request - Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome
Guidance for clinical laboratory providers regarding the formal request submission to CMS for a National
Coverage Determination (NCO) for allogeneic hematopoietic cell transplantation (HCT) for myelodysplastic syndrome (MDS) in the Medicare population.
Issued by: Centers for Medicare & Medicaid Services (CMS)
Issue Date: September 21, 2009
HHS is committed to making its websites and documents accessible to the widest possible audience, including individuals with disabilities. We are in the process of retroactively making some documents accessible. If you need assistance accessing an accessible version of this document, please reach out to the guidance@hhs.gov.
DISCLAIMER: The contents of this database lack the force and effect of law, except as authorized by law (including Medicare Advantage Rate Announcements and Advance Notices) or as specifically incorporated into a contract. The Department may not cite, use, or rely on any guidance that is not posted on the guidance repository, except to establish historical facts.